Satellos Bioscience Inc. announced six-month interim data from the TRAILHEAD study evaluating its investigational drug candidate SAT-3247 in adults living with Duchenne muscular dystrophy. The results showed reduced muscle fat fraction, increased total effort, stable strength, lower creatine kinase (CK), and a safety profile consistent with previously reported data. The findings suggest potential clinical benefits for a population with advanced muscle loss and fat infiltration.

The study involved four adults aged 21-28 who had previously completed the Phase 1a/b CL-101 study. All four participants showed a decline in muscle fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6. Additionally, all participants showed an increase in TE99C, a measure of maximum effort in the upper limbs, with a mean improvement of approximately 34% from a CL-101 baseline of 16.1 joules/kg to 21.6 joules/kg at TRAILHEAD month 6.

Key Findings from TRAILHEAD Interim Data

Across all measures of upper extremity strength, including handgrip and handheld dynamometry, participants demonstrated stability through the end of six months of treatment. The near-doubling of handgrip strength reported during the 28-day CL-101 study was maintained through to the end of month 6 of the TRAILHEAD follow-up period. Mean CK declined 38% from CL-101 baseline through month 6 in TRAILHEAD.

Supporting Measures and Safety

Mean PUL2.0 (Performance of the Upper Limb 2.0) increased by one point in two participants and remained stable in two participants from TRAILHEAD baseline through month 6. Mean PedsQL-MFS scores, a patient-reported quality-of-life measure, increased 6.94 points from CL-101 baseline (71.53 pts.) to month 6 in TRAILHEAD (78.47 pts.). SAT-3247 was well tolerated, with no serious treatment emergent adverse events (TEAEs), no TEAEs leading to withdrawal, and 100% compliance over an average of 186 days of drug exposure.

Frank Gleeson, co-founder and chief executive officer of Satellos, stated that the findings continue to show the biological activity of SAT-3247. The company remains on track to complete enrollment in BASECAMP, a pediatric DMD study, and to initiate US clinical trial sites for TRAILHEAD in the third quarter of this year.

Satellos Bioscience Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatment of Duchenne muscular dystrophy. This designation is designed to facilitate the development and expedite the review of new drugs to treat serious or life-threatening conditions and address unmet medical needs. The status may allow the company to engage more frequently with the FDA and utilize rolling reviews for future marketing applications.

"Fast Track designation represents an important validation of SAT-3247 and our commitment to transforming the treatment landscape for Duchenne," said Frank Gleeson, co-founder and chief executive officer of Satellos. He added that the recognition strengthens the momentum behind their clinical program, which already holds Orphan Drug and Rare Pediatric Disease designations. The company believes SAT-3247’s regenerative mechanism can address disease progression by re-establishing biological signals needed for muscle repair.

Key Designations and Benefits

The Fast Track process provides several advantages to companies developing therapies for serious conditions. These include:

• More frequent interactions with the FDA.
• Rolling review of future marketing applications.
• Eligibility for Accelerated Approval and Priority Review, if specific criteria are met.

Current Clinical Program

Satellos is currently advancing SAT-3247 through its ongoing Phase 2 studies. The program includes the BASECAMP and TRAILHEAD studies, which involve children and adults living with Duchenne. Additional data from these studies is expected in the second half of 2026.